HEXALEN
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HEXALEN is an oral small-molecule anticancer agent approved in 1990 by Eisai. The specific indication and mechanism of action are not disclosed in available data, but it is formulated as a capsule for systemic treatment. The drug operates as a legacy oncology asset in the company's portfolio.
LOE Approaching
LOE approaching signals a declining commercial priority; expect lean brand teams and focus on margin defense rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HEXALEN offers limited career advancement opportunities due to its LOE-approaching lifecycle stage and minimal linked job postings. Career value lies in cost-containment strategy, managed care negotiation, and defending market share against generics—ideal for professionals building expertise in mature asset management.
Brand ManagerField Sales Representative
Worked on HEXALEN at Eisai? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.